Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Product-news symbols : LLY save search
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Published: 2023-05-18 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.22%
H: 0.69%
C: 0.32%
trial
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
NKTR | News | $1.42 4.41% 3.89% 1.8K
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: -2.21%
nktr-358 t-cell therapeutics therapy
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.58%
H: 0.6%
C: 0.38%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.56%
H: 1.24%
C: 0.58%
ACIU | $2.38 -1.65% -1.68% 50
|
Health Technology
|
| O: 0.0%
H: 6.09%
C: 0.43%
year update financial results
Capstan Therapeutics Launches with $165M for Precise In Vivo Cell Engineering
Published: 2022-09-14 (Crawled : 15:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.24%
H: 1.5%
C: 0.78%
therapeutics
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Thrives
Published: 2022-07-28 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes
Published: 2021-05-10 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.38%
H: 0.22%
C: -0.72%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 1.54%
H: 0.17%
C: -0.32%
diabetes fda clearance fda insulin clearance
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
ABCL | $3.97 -1.0% -0.63% 1.6M
|
|
| O: -0.65%
H: 10.38%
C: 8.4%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
covid clinical trials antibody trial covid-19
Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
IDEA Pharma's 10th annual Pharmaceutical Innovation Index: Eli Lilly is the most innovative company for the first time
Published: 2021-04-21 (Crawled : 16:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.07%
H: 0.32%
C: 0.13%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.5%
H: 0.76%
C: -0.32%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.48%
H: 0.59%
C: 0.4%
pharma
EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer
Published: 2021-04-19 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.01%
H: 0.87%
C: 0.21%
Citing Variants, Eli Lilly Asks FDA To Revoke EUA for Single Antibody Therapy
Published: 2021-04-16 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.79%
H: 1.56%
C: 1.0%
fda therapy antibody
Lilly Closes Dermira’s Menlo Park Facility, Cutting 163 Jobs in the Process
Published: 2021-04-13 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.66%
H: 0.86%
C: 0.48%
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Published: 2021-02-26 (Crawled : 13:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 1.41%
H: 0.14%
C: -0.88%
covid therapy antibody covid-19
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $3.97 -1.0% -0.63% 1.6M
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Published: 2021-01-21 (Crawled : 15:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 1.21%
H: 0.5%
C: -0.66%
covid antibody risk trial
Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention
Published: 2020-12-21 (Crawled : 17:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -1.47%
H: 0.07%
C: -0.06%
covid drug phase 3 trial
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
RILY | $21.72 0.84% 32.09% 1.9M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
WIMI | $0.7254 5.45% 24.7% 4.1M
|
Technology Services
TPET | $0.3601 -4.51% 23.11% 11M
|
n/a
VLCN | $0.2946 26.38% 17.69% 390K
|
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
VRT 4 | $79.17 4.08% 15.6% 1.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
BOF | $1.17 6.36% 14.73% 15K
|
Your saved searches
Save your searches and get alerts when important news are released.